Dialing Down SUN1 for Laminopathies  by Suh, Yousin & Kennedy, Brian K.
microtubule nucleators are distributed
inhomogeneously. Two mechanisms,
which are not mutually exclusive, have
been proposed to date: a gradient of
nucleators around chromatin (Caudron
et al., 2005) and a microtubule-mediated
nucleationprocess (ClausenandRibbeck,
2007). In the future, the approach pre-
sented in this study—that is, combining
innovative experimental techniques with
mathematical modeling and simulations
(Loughlin et al., 2010)—may prove to be
helpful to investigate this question.ACKNOWLEDGMENTS
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Laminopathies, caused by mutations in A-type nuclear lamins, encompass a range of diseases,
including forms of progeria and muscular dystrophy. In this issue, Chen et al. provide evidence
that elevated expression of the nuclear inner membrane protein SUN1 drives pathology in multiple
laminopathies.Since their initial link to human disease,
A-type nuclear lamins have been the sub-
ject of intense scrutiny. Mutations, mostly
missense ones, in LMNA, the gene that
encodes all A-type lamins by alternative
splicing (lamins A and C are the most
prominent), cause diseases ranging from
dystrophic syndromes (including forms
of muscular dystrophy, lipodystrophy,
and dilated cardiomyopathy) to progeroid
disorders such as Hutchinson-Gilford
progeria syndrome (HGPS),whichpresent
with a rapid onset of a subset of patholo-
gies that are associated with normal
aging (Burtner and Kennedy, 2010). Why
do different mutations in a structural
component of the nucleus cause such
an array of debilitating disorders?
Mouse models of a wide spectrum of
laminopathies have been developed,
ranging from a knockout of the LMNA
gene, which dies at 6–8 weeks of agewith dilated cardiomyopathy and skeletal
muscle dystrophy (Sullivan et al., 1999),
to mice engineered to express human
disease mutations (Cohen and Stewart,
2008). The models generally recapitulate
their respective human disease pheno-
types and serve to uncover mechanisms
underlying pathophysiology and disease
progression. As a starting point for the
study by Chen et al. (2012), a double-
knockout mouse was created lacking
both A-type lamins and SUN1. SUN1
interacts with lamin A/C as components
of the linker of nucleoskeleton and cyto-
skeleton (LINC) complex, which mediates
crosstalk between the actin cytoskeleton
and the nucleus, leading to large-scale
nuclearmovementswithin thecell (Meinke
et al., 2011). The expectationwas that loss
of SUN1 would exacerbate the already
severe skeletal muscle and cardiac
phenotypes in the Lmna knockout, but tothe authors’ surprise, the reverse was
true. The Lmna/ Sun1/ mice survive
significantly longer than Lmna/ single
knockouts, resisting a range of Lmna/
pathologies, including lordokyphosis,
growth defects, reduced bone density,
and cardiac/skeletal muscle defects
(Figure 1; Chen et al., 2012).
There was already reason to believe
that the LINC complex might be linked
to laminopathies, as mutations in another
LINC component, Emerin, cause Emery-
Dreifuss muscular dystrophy. Loss of
A-type lamins leads to mislocalization of
other LINC components (Vaughan et al.,
2001, Muchir et al., 2003), but prior to
this study, it was not known how SUN1
would be affected. In embryonic fibro-
blasts from Lmna/ mice, Chen et al.
make two important observations—first
that SUN1 is highly overexpressed and
second that a substantial portion of the149, April 27, 2012 ª2012 Elsevier Inc. 509
Figure 1. Accumulation of Sun1 Is Pathogenic in Laminopathies
In dystrophic Lmna/ and progeric LmnaD9 mouse models, inner nuclear
envelope protein SUN1 accumulates. Removal of Sun1 in Lmna/ or LmnaD9
mice leads to reduced tissue pathologies and enhanced longevity. Likewise, in
human Hutchinson-Gilford progeria syndrome cells, SUN1 amasses, and
reducing its levels corrects nuclear and cellular defects. Hence, SUN1 may be
a prime target for interventions and therapies.protein is enriched in theGolgi
after localization to the
nuclear periphery is presum-
ably saturated (Chen et al.,
2012). RNAi-mediated knock-
down of SUN1 rescued
nuclear morphology and pro-
liferation defects. Thus,
reduced SUN1 expression
rescues cellular as well as
organismal defects associ-
ated with loss of A-type lam-
ins. Inhibition of SUN1 Golgi
localization also provided
partial rescue, suggesting
thathypermorphicor neomor-
phic functions of SUN1 in the
Golgi might drive pathology
in the Lmna/ context.
To investigate this sur-
prising finding further, Chen
et al. turned to anotherLMNA mutant mouse with progeroid
phenotypes and an interesting history.
The most common LMNAmutation giving
rise to HGPS is G608G, a silent mutation
that activates a cryptic splice site creating
an in-frame lamin A protein lacking 50
amino acids in theC terminus, termedpro-
gerin (Burtner and Kennedy, 2010). Mice
had been engineered to express an
Emery-Dreifuss human disease variant,
LMNA-L530P, with the expectation of
generating a better muscular dystrophy
model (Mounkes et al., 2003). Unexpect-
edly, a splicing defect in LMNA was
apparent in the L530P allele, removing
40 amino acids and rendering this mutant
allele similar but nonidentical to the pro-
gerin allele. These mice are referred to as
LmnaD9 mutants, and Chen et al. found
that LmnaD9/D9 Sun1/ double-mutant
mice live longer than their LmnaD9/D9
counterparts, with associated rescue of
cellular and organismal phenotypes
(Chen et al., 2012). That reduced expres-
sion of SUN1 rescues both Lmna/ and
LmnaD9/D9 is surprising because they are
thought to model different diseases.
Finally, Chen et al. investigated the role
of SUN1 in HGPS human fibroblasts.
Again, SUN1 is overexpressed in these
cells, consistent with an earlier report
(Haque et al., 2010). Reduction of SUN1
by RNAi improved nuclear morphology
and, in this case, rescued defects in
heterochromatin profiles and premature
senescence (Chen et al., 2012). However,510 Cell 149, April 27, 2012 ª2012 Elsevier Inthere was no excess SUN1 in the Golgi
detected; instead, increased SUN1 pro-
tein appeared to remain nuclear. The
reasons for this are unclear. It will be
important to resolve these differences in
future studies, as some of the potential
explanations run counter to the notion of
pathology being driven by toxicity in the
Golgi. One model put forward by the
authors is that HGPS human cells are
more sensitive to Golgi SUN1 and adapt
in culture to keep levels at a minimum.
Specific consequences resulting from ex-
pression of progerin per se may also be
involved in the differences between the
mouse models and human patient cells.
Whatdowemakeof thesefindings?The
take-home message is that SUN1 is over-
expressed inall three laminopathymodels,
and in each case, dialing SUN1 back
down rescues organismal and/or cellular
defects. In Lmna mouse models, this is
the first example of a genetic intervention
that enhances survival, making SUN1
a prime target in the pursuit of therapies.
A number of questions remain. How do
SUN1 levels become elevated in lamino-
pathies, and what happens during normal
aging? What is the mechanism by which
SUN1 overexpression leads to patholo-
gies, in particular, distinct phenotypes in
the two LMNA models? Remember that
loss of A-type lamin function in mouse
and humans causes cardiac and skeletal
muscle phenotypes, whereas dominant
gain-of-function LMNA mutations arec.thought to confer progeria.
One possibility is that these
genetic interpretations are
too simplistic. Progerin local-
izes to the nuclear periphery
and, in a heterozygous state,
brings normal lamin A with it
(Delbarre et al., 2006). This
would be predicted to result
in enhanced A-type lamin
function at the periphery and
reduced function in the inte-
rior. In this case, the conse-
quences of progerin expres-
sion should partially overlap
with that of complete loss of
A-type lamins in the knockout
but should also have distinct
features. Thus, progeroid
phenotypes may be a mixture
of gain and loss of A-type
lamin function.Like any important study, this report
by Chen et al. describes key new findings
and simultaneously raises questions
for future study. The answers to those
questions may unravel the mechanistic
underpinnings of multiple types of
laminopathies.REFERENCES
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